Sana Biotechnology Highlights Preclinical Data from Hypoimmune and Fusogen Platforms…
Hypoimmune (HIP)-modified CD19-directed CAR T cells have the potential to serve as a universal off-the-shelf therapy that provides long-term durability of response without immunosuppression…